Sensus Healthcare Reports Q3 2026 Revenue Decline Amid Product Mix Shifts
Sensus Healthcare (SRTS) reported third-quarter 2026 revenue of $6 million, a 13% decrease compared to the previous year. The decline was primarily driven by shifts in product mix and the absence of sales to the company's historically largest customer. Despite lower revenue, the company saw gross margin expansion to 55%, up from 39.1% last year, due to a higher proportion of high-margin SRT-100 units being shipped. The company reported a net loss of $1.5 million ($0.09 per share). While total system shipments reached 26 units, the company is focusing on diversifying its client base through new contracts with large private equity-backed dermatology groups. Looking ahead, management highlighted a proposed 26% increase in CMS hospital reimbursement rates for radiation treatment delivery codes, expected to take effect in early 2027.
Topics: cash position gross margin improvement net loss revenue decrease